Usefulness of Clopidogrel in Abolishing the Increased Risk of Reinfarction Associated With Higher Platelet Counts in Patients With ST-Elevation Myocardial Infarction (Results from CLARITY-TIMI 28)

American Journal of Cardiology

Volumn 98, Issue 6, 2006, Pages 761-763

  Gibson, C Michael ^a,b   Ly, Hung Q ^a   Murphy, Sabina A ^a   Ciaglo, Lauren N ^a   Southard, Matthew C ^a   Stein, Erica B ^a   Buros, Jacqueline L ^a   Sabatine, Marc S ^a   Cannon, Christopher P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; FIBRINOLYTIC AGENT; HEPARIN; PLACEBO;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; DISEASE ASSOCIATION; FEMALE; HEART INFARCTION; HEART REINFARCTION; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; ST SEGMENT ELEVATION; STATISTICAL MODEL; THROMBOCYTE COUNT; THROMBOCYTHEMIA; TREATMENT OUTCOME;

AGED; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; TICLOPIDINE;

EID: 33748039103     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.03.062     Document Type: Article

References (7)

1. Gibson C.M., Karha J., Murphy S.A., James D., Morrow D.A., Cannon C.P., Giugliano R.P., Antman E.M., and Braunwald E. Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis In Myocardial Infarction trials. J Am Coll Cardiol 42 (2003) 7-16
2. Hudson M.P., Granger C.B., Topol E.J., Pieper K.S., Armstrong P.W., Barbash G.I., Guerci A.D., Vahanian A., Califf R.M., and Ohman E.M. Early reinfarction after fibrinolysis: experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and Global Use of Strategies to Open occluded coronary arteries (GUSTO III) trials. Circulation 104 (2001) 1229-1235
3. Turakhia M.P., Murphy S.A., Pinto T.L., Antman E.M., Giugliano R.P., Cannon C.P., Braunwald E., and Gibson C.M. Association of platelet count with residual thrombus in the myocardial infarct-related coronary artery among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction. Am J Cardiol 94 (2004) 1406-1410
4. Martin J.F., Bath P.M., and Burr M.L. Influence of platelet size on outcome after myocardial infarction. Lancet 338 (1991) 1409-1411
5. Sabatine M.S., Cannon C.P., Gibson C.M., Lopez-Sendon J.L., Montalescot G., Theroux P., Claeys M.J., Cools F., Hill K.A., Skene A.M., et al., CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352 (2005) 1179-1189
6. Sabatine M.S., McCabe C.H., Gibson C.M., and Cannon C.P. Design and rationale of Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis In Myocardial Infarction (CLARITY-TIMI) 28 trial. Am Heart J 149 (2005) 227-233
7. Ridker P.M., Manson J.E., Buring J.E., Muller J.E., and Hennekens C.H. Circadian variation of acute myocardial infarction and the effect of low-dose aspirin in a randomized trial of physicians. Circulation 82 (1990) 897-902